Pharmacy-based minor ailment schemes are effective
Citation: Paudyal V, Watson MC, Sach T, et al. Are pharmacy-based minor ailment schemes a substitute for other service providers?: A systematic review. British Journal of General Practice. 2013 Jul 1;63(612):e472-81.
What is this? The COVID-19 pandemic is placing a strain on healthcare services. Existing research on pharmacy-based minor ailment schemes as a substitute for other service providers might provide useful information for policy makers.
In this systematic review, the authors searched for studies evaluating the outcomes of pharmacy-based minor ailment schemes on patient health, cost-related outcomes and shifting demand from high-cost services. They did not restrict their searches by type or language of publication and did the search for articles published between 2001 to 2011. They included 31 studies, all of which were conducted in the UK.
What was found: Pharmacy-based minor ailment schemes are effective for dealing with minor ailments, significantly lower the number of GP consultations and are less expensive than consultations with GPs.
The extent to which pharmacy-based minor ailment schemes can shift demand away from high-cost settings is uncertain.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.